UCP Glaucoma Surgery Technology Has Been Widely Recognized in The Ophthalmology Industry, Covering More Than 120 General Hospitals or Specialist Eye Care Hospitals in China

Updated By 2019-08-19

EyeOP1®, ETC’s product, was approved by CFDA in October 2017, and the company will focus on clinical and academic promotion in 2018. ETC actively promotes UCP technology and obtains support from authoritative professors at home and abroad. Famous academic leaders, experts and professors at home and abroad gave keynote speeches at the ophthalmologists’ conference of Zhejiang medical association, the annual ophthalmological conference of France, the national academy of ophthalmology and other authoritative industry conferences, and popularized UCP technology to attendees, which was widely recognized by the industry. By the end of the second quarter of 2019, EyeOP1® products and technologies were successfully used by more than 1100 patients from more than 120 general hospitals or eye hospitals in China, with remarkable results and good postoperative follow-up. Several top three grade A class hospitals in China gradually began the equipment bidding process and then they will purchase the equipment and instill them in the hospital.





Application of UCP technology in Qingdao Eye Hospital



Application of UCP technology in First Affiliated Hospital of Xi 'an Jiaotong University 



Application of UCP technology in First Affiliated Hospital of Kunming Medical University



Application of UCP technology in Shenyang Aier Ophthalmology




Application of UCP technology in Changsha Honglang Eye Hospital